Mousepox in Aged Mice

Information

  • Research Project
  • 7480299
  • ApplicationId
    7480299
  • Core Project Number
    R21AI077021
  • Full Project Number
    5R21AI077021-02
  • Serial Number
    77021
  • FOA Number
    RFA-AI-07-08
  • Sub Project Id
  • Project Start Date
    9/1/2007 - 17 years ago
  • Project End Date
    8/31/2010 - 14 years ago
  • Program Officer Name
    MILLER, LARA R.
  • Budget Start Date
    9/1/2008 - 16 years ago
  • Budget End Date
    8/31/2010 - 14 years ago
  • Fiscal Year
    2008
  • Support Year
    2
  • Suffix
  • Award Notice Date
    8/7/2008 - 16 years ago

Mousepox in Aged Mice

[unreadable] DESCRIPTION (provided by applicant): It is well known that resistance to viral infections and the ability to generate protective immunity following vaccination declines with age. While most of us have been vaccinated and are probably life-long immune to many common viral diseases, we have recently become more aware that emerging infectious diseases are possible, that pandemics with new strains of known viruses such as influenza are likely to occur, and that highly pathogenic microorganisms could be used as weapons. In each of these cases, the non-immune elderly would be at a much higher risk of disease and death than the young. Because the elderly represent a sizable proportion of the world population, understanding the reasons and trying to overcome the consequences of the age- dependent loss of natural and acquired resistance to viral diseases is of major public health interest. However, a direct detailed analysis of the loss of resistance to viral diseases in humans is not possible and appropriate animal models must be used. Mousepox is a frequently lethal disease of the mouse caused by the Orthopoxvirus (OPV) ectromelia virus (ECTV), a disease with remarkable resemblance to human smallpox (caused by the OPV variola virus, VARV) and monkeypox (caused by the homonym OPV). Some strains of mice, such as C57BL/6 (B6), are known to be naturally resistant to mousepox. However, we have recently found that B6 mice lose this resistance as they age. Thus, comparing the immune functions in response to primary ECTV infection of young and aged B6 mice offers an excellent model to understand the age-dependent loss of resistance to viral disease. Furthermore, because mousepox can be prevented with the smallpox vaccine, our new finding opens the opportunity to determine whether aged mice can be protected by vaccination. The overarching goal of this exploratory project will be to pinpoint the specific immune functions affected by age that correlate with the loss of natural and acquired resistance to mousepox. The long-term objective for this project is to understand the underpinnings behind any defective function discovered during this exploratory phase. Furthermore, we intend to find new methods to manipulate the immune response to restore resistance and improve vaccine efficacy in aged mice as a first approach to improve vaccine efficacy in elderly people. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R21
  • Administering IC
    AI
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    209689
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:209689\
  • Funding Mechanism
  • Study Section
    ZAI1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    INSTITUTE FOR CANCER RESEARCH
  • Organization Department
  • Organization DUNS
    872612445
  • Organization City
    Philadelphia
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    191112434
  • Organization District
    UNITED STATES